ARWR Stock Chart & Stats
$455.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$454.55 - $460.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$210.82B
Enterprise Value$8.50K
Total Cash (Recent Filing)$1.78B
Total Debt (Recent Filing)$1.37B
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Aug 04, 2026EPS Estimate
-22.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding140,857,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio28.34
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,727.54Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-54.49
Revenue Forecast (FY)$8.05B
ARWR FAQ
What was Arrowhead Pharmaceuticals, Inc.’s price range in the past 12 months?
Arrowhead Pharmaceuticals, Inc. lowest stock price was $454.55 and its highest was $460.00 in the past 12 months.
What is Arrowhead Pharmaceuticals, Inc.’s market cap?
Arrowhead Pharmaceuticals, Inc.’s market cap is $210.82B.
When is Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date?
Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 9 days.
How were Arrowhead Pharmaceuticals, Inc.’s earnings last quarter?
Arrowhead Pharmaceuticals, Inc. released its earnings results on May 07, 2026. The company reported -$16.283 earnings per share for the quarter, beating the consensus estimate of -$19.172 by $2.889.
Is Arrowhead Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals, Inc. pay dividends?
Arrowhead Pharmaceuticals, Inc. does not currently pay dividends.
What is Arrowhead Pharmaceuticals, Inc.’s EPS estimate?
Arrowhead Pharmaceuticals, Inc.’s EPS estimate is -22.36.
How many shares outstanding does Arrowhead Pharmaceuticals, Inc. have?
Arrowhead Pharmaceuticals, Inc. has 140,857,030 shares outstanding.
What happened to Arrowhead Pharmaceuticals, Inc.’s price movement after its last earnings report?
Arrowhead Pharmaceuticals, Inc. reported an EPS of -$16.283 in its last earnings report, beating expectations of -$19.172. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in MX:ARWR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrowhead Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,727.54 (― Downside)
$1,727.54 (― Downside)
Blogger Sentiment
Bullish
MX:ARWR Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
445.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.15%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
ARWR Stock 12 Month Forecast
Average Price Target
$1,727.54